Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men

Urology

Volumn 52, Issue 3, 1998, Pages 433-440

  Egawa, Shin ^a   Suyama, Kazuho ^a   Matsumoto, Kazumasa ^a   Satoh, Takefumi ^a   Uchida, Toyoaki ^a   Kuwao, Sadahito ^a   Koshiba, Ken ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; HUMAN; JAPAN; MALE; METASTASIS POTENTIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT; SEMINAL VESICLE DISEASE; STATISTICS;

AGED; BIOPSY, NEEDLE; GENITAL NEOPLASMS, MALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATIC NEOPLASMS; ROC CURVE; SEMINAL VESICLES;

EID: 0032169531     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00207-6     Document Type: Article

References (25)

1. 1. Egawa S, Koh H, Satoh T, et al: Preoperative serum prostate-specific antigen, clinical stage and Gleason sums as basis for predicting final pathological stage in Japanese patients with prostate cancer. Jpn J Clin Oncol 26: 438-444, 1996.
2. 2. Catalona WJ, and Bigg SW: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143: 538-544, 1990.
3. 3. Narayan P, Gajendran V, Taylor SP, et al: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 46: 205-212, 1995.
4. 4. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
5. 5. Bluestein DL, Bostwick DG, Bergstralh EJ, et al: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151: 1315-1320, 1994.
6. 6. Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152(Pt 2): 1714-1720, 1994.
7. 7. Frazier HA, Robertson JE, Humphrey PA, et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
8. 8. Walsh PC, Partin AW, and Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152(Pt 2): 1831-1836, 1994.
9. 9. Goto Y, Ohori M, Arakawa A, et al: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156: 1059-1063, 1996.
10. 10. Peller PA, Young DC, Marmaduke DP, et al: Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 75: 530-538, 1995.
11. 11. Ravery V, Schmid H-P, Toublanc M, et al: Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 78: 1079-1084, 1996.
12. 12. Cupp MR, Bostwick DG, Myers RP, et al: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153: 1543-1548, 1995.
13. 13. Hodge KK, McNeal JE, and Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142: 66-70, 1989.
14. 14. Klee GG, Dodge LA, Zincke H, et al: Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol 151: 94-98, 1994.
15. 15. Machida T, Ohishi Y, Wada T, et al: Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen. Acta Urol Japonica 39: 977-984, 1993.
16. 16. International Union Against Cancer, in Sobin LH, and Wittekind CH (Eds): TNM Classification of Malignant Tumours, 5th ed. New York, John Wiley & Sons, 1997, pp 170-173.
17. 17. Walsh PC: Radical retropubic prostatectomy: an anatomic approach, in Walsh PC, Retik AB, Stamey TA, et al (Eds): Campbell's Urology, 6th ed. Philadelphia, WB Saunders, 1992, vol 3, pp 2865-2886.
18. 18. Greene DR, Wheeler TM, Egawa S, et al: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 146: 1069-1076, 1991.
19. 19. Bostwick DG, Qian J, Bergstralh E, et al: Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 155: 1361-1367, 1996.
20. 20. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276: 615-619, 1996.
21. 21. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156: 137-143, 1996.
22. 22. Ackerman DA, Barry JM, Wicklund RA, et al: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150:1845-1850, 1993.
23. 23. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1e) prostate cancer. JAMA 271: 368-374, 1994.
24. 24. Badalament RA, Miller MC, Peller RA, et al: An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156: 1375-1380, 1996.
25. 25. Terris MK, McNeal JE, and Stamey TA: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 148: 829-832, 1992.